15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Group 3 innate lymphoid cells (ILC3s) are important regulators of the immune system, maintaining homeostasis in the presence of commensal bacteria, but activating immune defenses in response to microbial pathogens. ILC3s are a robust source of IL-22, a cytokine critical for stimulating the antimicrobial response. We sought to identify cytokines that can promote proliferation and induce or maintain IL-22 production by ILC3s and determine a molecular mechanism for this process. We identified IL-18 as a cytokine that cooperates with an ILC3 survival factor, IL-15, to induce proliferation of human ILC3s, as well as induce and maintain IL-22 production. To determine a mechanism of action, we examined the NF-κB pathway, which is activated by IL-18 signaling. We found that the NF-κB complex signaling component, p65, binds to the proximal region of theIL22promoter and promotes transcriptional activity. Finally, we observed that CD11c+dendritic cells expressing IL-18 are found in close proximity to ILC3s in human tonsils in situ. Therefore, we identify a new mechanism by which human ILC3s proliferate and produce IL-22, and identify NF-κB as a potential therapeutic target to be considered in pathologic states characterized by overproduction of IL-18 and/or IL-22.

          Related collections

          Author and article information

          Journal
          J. Immunol.
          Journal of immunology (Baltimore, Md. : 1950)
          The American Association of Immunologists
          1550-6606
          0022-1767
          October 01 2017
          : 199
          : 7
          Affiliations
          [1 ] Medical Scientist Training Program, Ohio State University, Columbus, OH 43210.
          [2 ] The James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
          [3 ] Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210.
          [4 ] Department of Molecular Genetics, College of Biological Sciences, The Ohio State University, Columbus, OH 43210.
          [5 ] Department of Pathology, The Ohio State University, Columbus, OH 43210.
          [6 ] Center for Biostatistics, Department of Bioinformatics, The Ohio State University, Columbus, OH 43210; and.
          [7 ] The James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; michael.caligiuri@osumc.edu jianhua.yu@osumc.edu.
          [8 ] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
          Article
          jimmunol.1601554 NIHMS896889
          10.4049/jimmunol.1601554
          5624342
          28842466
          e27a6cc5-aef2-4f3c-b3a9-b1c132dee0c0
          History

          Comments

          Comment on this article